🎀 GYN Oncology — 2026-W43

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Review in Annals of Oncology of emerging targeted and immune-based therapies in gynecologic cancers, including DDR inhibitors, ADCs, bispecifics and cell therapies. Informs the evolving biomarker-driven treatment landscape and early-phase drug development in recurrent disease.

Phase 1 trial of a personalized neoantigen peptide vaccine with delayed anti-PD-1 in platinum-sensitive high-grade ovarian cancer after chemotherapy, published in Nature Medicine. Shows feasibility, acceptable safety and signs of immune activity, but remains early-stage and investigational.

Narrative review of histotype-specific molecular alterations and targeted therapies in epithelial ovarian cancer, published in Cancer and Metastasis Reviews. Proposes a histotype-molecular stratification framework that may inform precision treatment, though clinical applicability remains unproven.

Nested case-control translational study of extracellular vesicle proteomics in high-grade serous ovarian cancer, published in Gynecologic Oncology. Suggests an EV signature may improve diagnostic accuracy over CA-125, but it is a diagnostic tool without a direct treatment implication.

Exploratory molecular profiling from the phase 2 MITO END-3 study in advanced or recurrent endometrial cancer, published in JCO Precision Oncology. It shows PIK3CA mutations are common and potentially targetable with PI3K inhibitors, but is hypothesis-generating.

Small retrospective case series in women living with HIV and ovarian cancer, published in Frontiers in Oncology. Offers limited real-world tolerability and immune-monitoring observations for chemotherapy, bevacizumab and PARP inhibitors in an underrepresented group, but the very small size limits conclusions.

Trial-in-progress description of the BEHOLD-1 and -2 phase 1/2 studies of a B7-H4-directed antibody-drug conjugate in advanced solid tumors, including endometrial and ovarian cancers, published in Int J Gynecol Cancer. Reports design only with no results, so it informs awareness of an emerging agent but does not change practice.

Small exploratory genomic profiling study in advanced/recurrent endometrial cancer, published in Gynecologic Oncology. Suggests KRAS-TP53 co-mutation marks poor survival and chemoresistance, which is hypothesis-generating and not yet actionable for treatment selection.

Single-arm phase 2 trial in locally advanced cervical cancer receiving concurrent platinum-doublet chemoradiotherapy, published in Cancer Medicine. Combining bone marrow-sparing radiotherapy with prophylactic G-CSF met its goal of reducing severe neutropenia, offering a supportive-care strategy pending confirmation.

Single-institution retrospective cohort in recurrent endometrial and cervical cancer, published in Gynecologic Oncology. Suggests immunotherapy retreatment after prior checkpoint inhibitor has activity in selected patients with acceptable toxicity, though evidence is limited by small size.

Translational biomarker analysis of the randomized phase 2 NRG-GY012 trial in recurrent or metastatic endometrial cancer, published in Cancer. Explores blood-based markers such as IL-6, OPN and PlGF as potential predictors of benefit from cediranib or olaparib, though the primary IL-6 cutpoint did not validate.

Retrospective NCDB cohort of older women with stage III-IV endometrial cancer, published in Gynecologic Oncology. Shows immunotherapy uptake rising over time but with persistent age and racial/ethnic disparities, highlighting gaps in access to proven therapy.

Propensity-matched real-world cohort study in advanced or recurrent endometrial cancer treated with second-line pembrolizumab plus lenvatinib, published in Cancers. Suggests a longer treatment-free interval after first-line chemotherapy is associated with better survival, informing prognosis and counseling but not a treatment choice.

Prospective single-center observational study of unselected germline multigene testing in ovarian carcinoma, published in Gynecologic Oncology. Supports feasibility of universal germline testing and informs germline-first versus tumor-first BRCA testing strategies.

Retrospective single-institution cohort in surgically staged stage I uterine serous carcinoma, published in Gynecol Oncol. Suggests adjuvant chemotherapy is associated with better survival when myoinvasion is present but not without it, and flags positive cytology as a poor prognostic factor.